Diagnostic Imaging

No therapy without prior diagnosis

The success of later treatment depends on making a diagnosis as early as possible which makes great demands on diagnostics. Bayer Schering Pharma is exploring substances that label certain molecules – e.g. proteins or cells in the body – in such a way that these substances can be can be recognized and measured.

As a pioneer in many areas of diagnostic imaging, our scientists have been successful with innovations again and again. For instance, by using magnetic resonance imaging, it is possible in the meantime to selectively visualize specific organs in high resolution. But the development goes further. New procedures aim for identifying specific diseases even more targeted and precise.

View Podcast

Audio: Positive study with substance to support diagnosis of alzheimers disease

Molecular imaging

Molecular imaging comprises diagnostic procedures that particularly allow the detection of precursors of disease. Such procedures are expected to provide not only earlier but also more accurate detection of, for example, tumors and central nervous system disorders.

In the field of molecular imaging, we are pursuing promising approaches with innovative carrier molecules that bind highly specifically to certain cell structures. This will facilitate the development of procedures for visualizing disease-specific biological processes.

In oncology, for example, target-specific molecules that target proteins associated with the angiogenesis of solid tumors are expected to improve diagnostic accuracy. In the central nervous system, other target-specific molecules may provide early diagnosis of neurodegenerative diseases.

As part of our research cooperation program with the U.S. company AVID Radiopharmaceuticals, Inc., Bayer Schering Pharma AG is developing new substances for the early diagnosis of Alzheimer’s disease. In 2006, we also set up a research program with Stanford University in the field of molecular imaging.